High-Purity PEG Lipids for Repeated LNP Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticle (LNP) formulations face challenges in achieving ideal physical characteristics and bioperformance, including susceptibility to immune recognition and clearance, which limits dosing frequency and can cause adverse effects.
Innovation Solution
The use of high-purity PEG lipids with a purity of 87% or greater in LNP formulations, which reduces immune recognition and clearance, thereby allowing more frequent dosing without loss of activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional PEG lipids with lower purity are used in LNP formulations, then manufacturing cost and ease of manufacture are improved, but immune recognition and clearance increase, limiting dosing frequency
Solution Approach 1:
The patent applies parameter changes by specifying a minimum purity threshold (87%) for PEG lipids used in LNP formulations. This quantitative parameter change resolves the contradiction by establishing that higher purity PEG lipids reduce immune recognition and clearance, enabling repeated dosing within two weeks while maintaining manufacturing feasibility through established purification protocols
2Object-affected harmful factors
If PEG lipids are used to cloak agents and reduce antigenicity, then immunogenicity is reduced, but the ability to repeatedly dose without loss of activity is limited
Solution Approach 1:
The patent resolves this contradiction by changing the purity parameter of PEG lipids to at least 87%. This parameter change maintains the cloaking effect that reduces antigenicity while simultaneously enabling repeated dosing within two weeks, thereby extending the effective duration of action and dosing frequency
3Reliability
If LNP formulations are designed to achieve ideal physical characteristics, then bioperformance is improved, but susceptibility to immune recognition and clearance remains
Solution Approach 1:
The patent applies composite materials by combining high-purity PEG lipids (at least 87% pure) with other lipid components in LNP formulations. This composite approach achieves ideal physical characteristics and bioperformance while the high purity of the PEG lipid component specifically addresses immune recognition and clearance, enabling repeated dosing
Data Source
AI summary
The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations. Therefore, the present disclosure provides PEG lipids at a recommended purity, e.g., for use in formulations, such as LNP formulations. The present disclosure also provides LNPs comprising the high-purity PEG lipids, and methods for delivering therapeutic agents to a subject using the same.